A new conjugate vaccine is highly effective (93-100%) at preventing invasive pneumococcal disease (IPD; meningitis, sepsis, bacteremic pneumonia, and other blood-borne infections) in infants younger than 2 years who are the most vulnerable to infection, according to new research published Online...
According to a computer-based cost-effectiveness analysis in the February issue of JAMA, recommending the use of the 13-valent pneumococcal conjugate vaccine (PCV13) could possibly prevent more pneumococcal disease than the current 23-valent pneumococcal polysaccharide vaccine (PPSV23)...
Giving patients both the herpes zoster and pneumococcal vaccines simultaneously does not seem to undermine the zoster vaccine's protective effect, despite FDA concerns to the contrary, researchers from Kaiser Permanente wrote in the journal Vaccine. The package insert of the zoster vaccine says...
The WHO "has granted prequalification status to Pfizer Inc.'s children's pneumococcal vaccine, Prevenar 13, paving the way for United Nations agencies and governments to start ordering the product," the Associated Press reports (8/23). The WHO decision comes after Pfizer in March entered...
The FDA on Monday said it's entering into a collaboration with the nonprofit group PATH "to speed creation of a pneumococcal vaccine for children in developing nations," United Press International reports (2/1). "The bacteria, Streptococcus pneumoniae, can cause fatal infections of the ear...